Opinion for the court filed by Circuit Judge Dyk, in which Prost, Chief Judge, joins.
Dissenting Opinion filed by Circuit Judge Stoll.
Dyk, Circuit Judge.
The United States Patent and Trademark Office (“USPTO”) rejected claims 20, 26, and 27 of U.S. Patent Application No. 10/008,955 (“’955 patent application”) on the ground that the claims would have been obvious. NantKwest sought review in district court, pursuant to 35 U.S.C. § 145, asserting that claims 20, 26, and 27 of the application were nonobvious. The district court granted the USPTO’s motion for summary judgment of obviousness. Nant-Kwest appeals. We affirm.
Background
NantKwest is the assignee of the patent application at issue, filed by Hans Klin-gemann (“patent applicant”), directed to the use of a specific type of immune cells for treating cancer.
The immune system can be divided into its innate and adaptive responses. The innate immune response—which is the first line of defense—comprises immune cells like natural killer (“NK”) cells that rapidly attack anything that they sense as foreign. NK cells generally have limited target-recognition specificity and attack rather indiscriminately. The adaptive immune response—which is the second line of defense—comprises immune cells like T cells that attack specific foreign antigens that they have been trained to recognize. The adaptive immune response is thus slower [866]*866but more target-specific. NK cells and T cells have different cell surface proteins and respond to certain target cell receptors differently. The patent application here concerns the use of a particular cell line1 of NK cells—NK-92.
Despite these differences between NK cells and T cells, throughout the 1980s and 1990s, various prior art references taught that both T cells and NK cells were capable of lysing (destroying) cancer cells. These references described in vitro, ex vivo and in vivo experiments demonstrating this ability. By 1997, NK cells and T cells were the only two types of immune cells known “to recognize and lyse tumor cells in vivo in mammals.” J.A. 779-80.
Two specific prior art references are involved here. First, U.S. Patent No. 5,272,082, by Santoli et al. (“Santoli”), taught that a specific cell line of T cells, TALL-104, can be used in vivo to treat cancer. Second, Gong, Maki, and Klingem-ann (the ’955 patent applicant) published a study (“Gong”) that taught that a specific NK cell line, NK-92, can lyse cancer cells in vitro with high efficacy. The question here is whether these references rendered the ’955 application’s claims obvious.
On December 7, 2001, the patent application was filed with a priority date of April 30, 1997. Claim 20, an independent claim on appeal here, provides
A method of treating a cancer in vivo in a mammal comprising the step of administering to the mammal a medium comprising an NK-92 cell line ATCC Deposit No. CRL-2407, wherein said cancer is recognized and lysed by said NK-92 cell line.
J.A. 5. Also on appeal are two dependent claims. Claim 26 teaches that “[t]he method of treating a cancer described in claim 20 wherein the route of administration of the cells to the mammal is intravenous and the mammal is human.” Id. Claim 27 teaches that “[t]he method of- treating a cancer described in claim 20 further comprising the step of administering to said mammal a cytokine that promotes the growth of said NK-92 cell line.” Id.
The USPTO Examiner rejected the claims at issue and found that “it would have been prima facie obvious to a person of ordinary skill in the art ... in April 1997 to combine the teachings of Santoli and Gong to arrive at the claimed method because Gong ... teaches use of NK-92 cells to lyse tumor cells, while Santoli ... teaches in vivo use of cytotoxic cell lines.” J.A. 8 (internal quotation marks omitted).
The applicant then appealed to the Board of Patent Appeals and Interferences (“Board”). The Board affirmed the Examiner’s rejection on the ground that a person of ordinary skill in the art “would have been motivated to replace the TALL-104 cells in Santoli’s method with NK-92 cells based on Gong’s disclosure that NK-92 cells spontaneously kill [leukemia and lymphoma cancer] cells with high efficiency.” J.A. 10 (internal quotation marks omitted).
Pursuant to 35 U.S.C. § 145, NantKwest then filed a complaint in district court, seeking judgment that claims 20, 26, and 27 of the patent application were nonobvious. The USPTO moved for summary judgment. In response, NantKwest argued that this case involves disputes of factual issues that cannot be resolved on summary judgment, relying on expert reports from [867]*867Dr. Miller (“Miller”) and new references submitted for the § 145 proceeding. The district court granted summary judgment “because there is no genuine material factual dispute as to whether the invention claimed in the [patent application] was obvious over the prior art, as found by both the Examiner and the Board.” J.A. 15.
NantKwest appeals. We have jurisdiction under 28 U.S.C. § 1295(a)(1).
Discussion
I
This court reviews the district court’s grant or denial of summary judgment de novo. MicroStrategy Inc. v. Bus. Objects, S.A., 429 F.3d 1344, 1349 (Fed. Cir. 2005) (citations omitted). Summary judgment may be granted only “if the movant shows that there is no genuine dispute as to any material fact.” Fed. R. Civ. P. 56(a). Claim construction is an issue of law that we review de novo where, as here, there is no relevant extrinsic evidence. Teva Pharm. USA, Inc. v. Sandoz, Inc., — U.S. -, 135 S.Ct. 831, 841, — L.Ed.2d - (2015).
A patent is obvious if “a skilled artisan would have been motivated to combine the teachings of the prior art references to achieve the claimed invention, and that the skilled artisan would have had a reasonable expectation of success in doing so.” Procter & Gamble Co. v. Teva Pharm. USA, Inc., 566 F.3d 989, 994 (Fed. Cir. 2009) (internal quotation marks omitted).
II
NantKwest contends that we should reverse the grant of summary judgment because the district court used an incorrect claim construction. Initially, the district court construed “cancer” to mean a “plurality or multiple cancer cells.” J.A. 16. However, in addressing the reasonable expectation of success, the court appeared to consider “cancer” as meaning “one or more cancer cells.” J.A. 22. We agree with NantKwest that this is an incorrect construction of “cancer.” The correct construction of the claim term “treating a cancer” “require[s] lysis of many cells, in order to accomplish the goal of treating cancer,” and not merely lysing one or a few cancer cells. J.A. 722.
However, the district court’s erroneous claim construction creates no basis for reversal. First, we review the district court’s decision de novo. In addressing the issue of obviousness, we will use the correct construction, which renders the district court’s erroneous construction harmless error. Second, there is no assertion here that the relevant prior art references taught methods that only lysed one cancer cell or otherwise lysed insufficient numbers of cells for treating cancer.
Ill
a
Under 35 U.S.C. § 145,
[a]n applicant dissatisfied with the decision of the [Board] ... may .., have remedy by civil action against the Director in [district court].... The court may adjudge that such applicant is entitled to receive a patent for his invention, as specified in any of his claims involved in the decision of the [Board], as the facts in the case may appear....
In § 145 proceedings, “the district court may consider new evidence” presented by the applicant that was not before the Board. Kappos v. Hyatt, 566 U.S. 431, 132 S.Ct. 1690, 1696, 182 L.Ed.2d 704 (2012). If there are genuine issues of material fact, “the district court must make de novo factual findings that take account of both the new evidence and the administrative record before the PTO.” Id. at 1701.
[868]*868We agree with the district court that there is no material dispute that the combination of Santoli and Gong used here produced the invention and that persons of ordinary skill in the art would have been motivated to combine Santoli and Gong.
Santoli was an important advance because it showed that T cells from a cell line, not belonging to a patient, can be administered into a patient to produce in vivo therapeutic effects. Such an approach is called “allogeneic” or “adoptive immu-notherapy.” Santoli specifically taught that the TALL-104 cell line can be used in adoptive immunotherapy in vivo for lysing cancer cells.2
. Gong taught that the NK-92 cell line showed in vitro efficacy in lysing cancer cells. In fact, NK-92 was found to have “high efficiency” in lysing the same leukemia tumor cell type as TALL-104 did. See J.A. 128, 142. Both TALL-104 and NK-92 lysed cancer cells via the same mechanism, i.e., in a “non-MHC-restricted” manner, in which they do not require presentation of antigens on the MHC cell surface proteins of the tumor cells. J.A. 131,145.
Prior art publications by the patent applicant himself indicated that there was a motivation to seek clinical applications for the NK-92 cell line. For example, Gong noted that “[b]ecause of their ability to lyse malignant cells, NK ... cells have been utilized in several clinical trials in cancer patients.” J.A. 140. In a separate publication, Klingemann et al. cited to the fact that because “NK-92 cells ... can lyse [tumor cells] in vitro,” the authors wanted “[t]o test the suitability NK-92 cells for ex vivo purging.”3 J.A. 344. While the appellant is correct that these experiments are different from allogeneic in vivo therapy, in that they used the patient’s own NK cells, they indisputably indicate that skilled artisans were motivated to pursue clinical applications for NK cells and the NK-92 cell line.
Indeed, the ’955 patent application itself referred to Gong to describe the superior qualities of the NK-92 cell line. See, e.g., ’955' patent application, ¶ 50 (“The NK-92 cell line has been described by Gong et al. (1994)”); id. at ¶ 74 (“NK-92 cells (Gong et al. (1994)) were derived from cells obtained from' a patient suffering from non-Hodgkin’s lymphoma.”). The patent application highlighted NK-92’s “superior” in vitro efficacy (as well as the later-determined in vivo efficacy), compared against other immune cells, as “activities [that] are ... unexpected by a worker in the field of tumor cytotherapy.” Id. at ¶ 121. The patent application also teaches that NK-92’s in vitro efficacy was “superi- or to those activities manifested by the known preparations of cytolytic cells normally present in humans,” which suggests [869]*869NK-92’s therapeutic utility based on in vitro data. Id. In fact, the ’955 patent application concluded from in vitro data that “the NK-92 cells of the invention are surprisingly and significantly more effective in lysing patient-derived tumor cells ... than ... the cells from [the TALL-104] cell line[ ] known in the field.” Id. at ¶ 104.
Santoli taught that “[t]here remains a need in the art for therapeutic methods ... for cancers which can utilize cytotoxic T cell lines and avoid the present need ... for patient’s own killer cells.” J.A. 130, col. 2, II. 33-37. Santoli thus provided an explicit suggestion to use cell lines (alloge-neic therapy) in cancer treatments because of their greater availability. In fact, the ’955 patent application itself recognized that prior investigators turned to al-logeneic therapy in preference to using a patient’s own cells. See ’955 patent application, ¶ 9 (To overcome the “major obstacle” of “expanding] NK cells ... in vivo” for clinical use, “many investigators have turned to the use of established NK-like cell lines.”). Thus, prior art references on successful in vivo therapy using non-allo-geneic NK cells taught toward using cell lines.
Finally, there were specific studies undertaken to determine whether the NK-92 cell line would be useful for in vivo therapy. Yan et al. (“Yan”) is a prior art reference relied on by the Board, in which investigators compared the in vitro effica-cies between TALL-104 and NK-92 cell lines against various tumors, in order to study the potential of using these cell lines for in vivo therapy. J.A. 226 (“To study the potential of using biological reagents in adoptive immunotherapy, we tested the tu-moricidal capacity of T104 [and] NK92.”). Yan concluded that the in vitro efficacy of NK-92 was even greater than the in vitro efficacy of TALL-104, which had already been used for in vivo therapy. Through this head-to-head comparison, Yan taught persons skilled in the art to combine the teachings of Santoli—using a cell line in adoptive immunotherapy—with the teachings of Gong—the use of the NK-92 cell line.
b
We also find that it would have been at least obvious for skilled artisans to try to combine the teachings of Santoli and Gong.
When there is a ... problem and there are a finite number-of identified, predictable solutions, a person of ordinary skill has good reason to pursue the known options .... If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under § 103.
KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 421, 127 S.Ct. 1727, 167 L.Ed.2d 705 (2007).' Generally, the only situations where this does not apply is where “the inventor would have had to try all possibilities in a field unreduced by direction of the prior art ... [or] where vague prior art does not guide an inventor toward a particular solution.” Bayer Schering Pharma AG v. Barr Lab., Inc., 575 F.3d 1341, 1347 (Fed. Cir. 2009).
Even NantKwest’s expert conceded that in 1997, skilled artisans knew that NK cells and T cells were the only two types of immune cells known to have antitumor efficacy. Moreover, both Santoli and Gong recognized that TALL-104 and NK-92 cells attack cancer cells via the same mechar nism, which induced skilled artisans like Yan to compare the efficacies of these two cell lines. Thus, TALL-104 and NK-92 were known to be similar and were among a very limited number of immune cells for [870]*870use in anticancer therapy. Given the limited number of possibilities in the prior art and the many explicit suggestions “toward a particular solution,” Bayer, 575 F.3d at 1347, we conclude that combining the teachings of Santoli and Gong would have been at least obvious to try.
IV
NantKwest claims that expert reports by Dr. Miller submitted for the first time in the district court proceeding and new prior art references also submitted for the § 145 proceeding raise genuine disputes of material fact about the reasonable likelihood of success for combining Gong -with Santoli. We disagree.
Our cases recognize that there is no general rule that a skilled artisan cannot reasonably extrapolate in vivo success from in vitro results. “Obviousness does not require absolute predictability of success. Indeed, for many inventions that seem quite obvious, there is no absolute predictability of success until the invention is reduced to practice.” In re O’Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988). “[providing proof sufficient to justify conducting in vivo procedures on humans, while useful, is not a test of patentability.” PharmaStem Therapeutics, Inc. v. ViaCell, Inc., 491 F.3d 1342, 1364 (Fed. Cir. 2007).
Rather, our cases hold that whether the skilled artisan can extrapolate in vivo success from in vitro results is highly fact-specific. See In re Gangadharam, 889 F.2d 1101, 1989 WL 127023 (Fed. Cir. 1989) (“The issue ... is not whether in vitro results can be used to predict in vivo success; rather it’s simply whether the [USPTO], in this case, carried its burden of proving a prima facie case of obviousness of the claimed invention.” (emphasis in original)); In re Carroll, 601 F.2d 1184, 1186 (C.C.P.A. 1979) (holding that there was teaching away because a witness had stated that in vitro testing was unreliable for in vivo effectiveness in a specific context).
The fact that in vitro success does not always translate into in vivo success cannot defeat summary judgment. “[Obviousness cannot be avoided simply by a showing of some degree of unpredictability in the art so long as there was a reasonable probability of success.” Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1364 (Fed. Cir. 2007). Indeed, NantKwest itself simply argues that “[pjositive results in vitro do not necessarily establish a reasonable probability of success for therapeutic use of that drug in vivo.” Appellant Br. 43 (emphasis added). But here, as we have discussed 'above, there is over-whelming specific evidence that a skilled artisan could reasonably extrapolate from the in vitro data with respect to TALL-104 and NK-92 that would reasonably teach their successful substitution in vivo.4
[871]*871However, the appellant asserts five specific material disputes as to whether in vitro success here would translate into in vivo success.
First, NantKwest argues that Miller shows that there is a teaching away from using unmodified NK-92 cells in vivo because Santoli used TALL-104 cells modified to contain a “suicide gene.” Appellant Br. 38. Santoli thus “strongly discourages the skilled artisan from attempting to introduce unmodified [immune] cells into a new host” without this genetic modification, because such, cells may cause cancer. J.A. 392.
NantKwest conceded during oral argument that the claim language here does not require administering “unmodified” NK-92 cells; that is, administering modified NK-92 cells is encompassed by the claimed invention. Oral Arg. 33:40-56. Therefore, whether Santoli teaches away from using unmodified NK-92 cells is irrelevant. Furthermore, the prior art had disclosed that TALL-104 cells could be “lethally irradiated,” so that they became “non-proliferating,” without sacrificing TALL-104’s ability to lyse cancer cells. J.A. 183. There is no dispute that there would be motivation to irradiate cell lines to address this problem if it arose.5 Thus, safely using a genetically unmodified immune cell line was already taught in the prior art.
Second, NantKwest argues that Miller shows that there is a teaching away from using allogeneic NK-92 therapy because “[i]t was not well understood at the time of the invention whether allogeneic NK cells would be subject to [attack by the] foreign host or whether [the administered NK cells would] indiscriminate[ly] kill[ ] ... host cells.” J.A. 411.
This was a broad and general concern known to skilled artisans. In fact, USPTO expert Dr. Lanier agreed that the “use of foreign immune cells in allogeneic therapies may be associated with” reactions from the host and the foreign cells against each other. J.A. 573. It would be necessary “to test immune cells for reactivity and cytotoxicity against allogeneic normal host cells in vitro prior to developing treatments ... in vivo.” Id. There was no testimony here that such an adverse reaction was likely in this context, and there was no testimony that this well-known, general phenomenon (that administering foreign cells into a host could cause untoward reactions) would prevent a skilled artisan from trying NK-92 cells in vivo while undertaking the necessary and known precautions. If the need for such pre-administration trials could prevent securing a patent, then no patent on in vivo therapy would ever issue before clinical trials were complete. While that appears to have been Dr. Miller’s own view,6 that view [872]*872does not correspond to the existing standard for patentability. See PharmaStem, 491 F.3d at 1364; Pfizer, 480 F.3d at 1364 (“[A] rule of law equating unpredictability to patentability ... would mean that any new [drug] ... would be separately patentable ... [after its] properties ... [are] verified through testing.”).
Third, NantKwest argues that Yan taught away from substituting NK-92 for TALL-104 because it showed that TALL-104 and NK-92 “differed in cytolytic activity against” the tumors tested. Appellant Br. 34 n.6. However, the appellant failed to mention that this difference was actually the fact that “[t]he NK92 [cell line] was highly cytotoxic towards all” of the tumors tested, while TALL-104 only lysed four out of the thirteen tumors tested. J.A. 226. Therefore, NK-92 was much more efficacious than TALL-104, which would teach a skilled artisan toward the substitution.
Fourth, NantKwest argues that Yan does not provide a motivation to combine because it cautioned that extrapolating im-munotherapy results from one context to another may be unpredictable. Specifically, Yan stated that “our studies suggest that [immune cells’] cytotoxic activity towards [cancer cells derived from laboratory] cell lines cannot be extrapolated to [cancer] cells derived directly from patients. ... [S]uch ... immunotherapy .., must be accompanied by careful study of the unique patterns of activity” of the antitu-mor immune cells used. J.A. 226. Contrary to Miller’s assertion that this caveat “admonishes against relying on in vitro tests to predict in vivo activity,” J.A. 439, Yan is not in fact comparing in vitro and in vivo efficacies. In fact, Yan contains no in vivo experiments. Rather, Yan is cautioning against extrapolating lysis results against tumors derived from cell lines to tumors derived directly from patients.
And as the data shows, this caveat applies only to TALL-104, but not NK-92.7 As discussed above, TALL-104 lysed three out of four types of cancer cells derived from laboratory cell lines, but only one out of nine types of cancer cells derived directly from patients. In the same comparison, NK-92 lysed all of the four types of cancers derived from cell lines and all of the nine types of cancers derived directly from patients. In other words, NK-92 showed no difference in lysis efficacy against laboratory cell line cancers and patient-derived cancers. Therefore, unlike TALL-104, which lyses cancer cells differently depending on their source, NK-92’s efficacy appears to not be context-dependent. See Yan, J.A. 226.
Fifth, NantKwest makes much of the differences between T cells’ and NK cells’ cell-surface receptors, to argue that these differences would have made it difficult to extrapolate NK-92 behavior from TALL-104’s. However, while Miller indeed highlights these differences, he conceded that “NK-92 killing and T-ALL killing [of cancer cells] has not, to my knowledge, in [1997], been associated with the[ir] specific receptor pattern.” Miller Deposition, EOF 59-1, at 34. Therefore, these cell-surface receptor differences are not material for the two cell lines’ similar ability to lyse cancer cells.
V
NantKwest argues that even against a prima facie case of obviousness, it had presented secondary considerations of nonobviousness that “may raise a genuine issue of material fact that precludes sum[873]*873mary judgment.” Appellant Br. 61. “[E]vi-dence ... of ... secondary considerations must always when present be considered en route to a determination of obviousness.” In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, 676 F.3d 1063, 1075 (Fed. Cir. 2012) (quotation marks and citation omitted). However, “[flor ... secondary considerations to be accorded substantial weight, its proponent must establish a nexus between the evidence and the merits of the claimed invention.... Moreover, secondary considerations ... cannot overcome a strong prima facie case of obviousness.” Wyers v. Master Lock Co., 616 F.3d 1231, 1246 (Fed. Cir. 2010) (quotation marks and citation omitted).
For secondary considerations of nonobviousness, NantKwest presents a news article announcing a $48 million investment in NantKwest as evidence of commercial success, and some results from NK-92’s Phase I clinical trials as evidence of unexpected results.
With respect to the investment, we agree with the district court that there is no direct nexus between the $48 million stock purchase and the merits of the claimed invention to demonstrate commercial success, The report indicates that the stock purchase was made for corporate control purposes.
NantKwest also contends that it “presented evidence of the clinical success of NK-92 in vivo therapy ... [that] has demonstrated unexpected, superior results in two recent ... Phase I” clinical trials. Appellant Br. 57. There is no evidence that the efficacy results were unexpected compared to what was expected based on the in vitro data. Indeed, as discussed above, the in vitro data suggested that the in vivo trials would be successful. With respect to the Phase I trials' safety results, there was no support for the conclusion that the NK-92 cell line was surprisingly safer than the TALL-104 cell line therapy. See Miller, J.A. 393-94 ¶ 48, J.A. 396 ¶ 53.
We conclude that the district court properly granted summary judgment that claims 20, 26, and 27 were invalid as obvious.
VI
The dissent appears to agree that there is substantial evidence supporting the district court’s finding of obviousness. However, the dissent concludes that NantKwest submitted contrary evidence that raises genuine issues of material fact.
The two cases cited by the dissent for the proposition that “lesser evidence [than what is presented here was] sufficient to reverse rejections by the PTO in the past” are clearly distinguishable. Dissent Op. 876-77. As discussed above, both Carroll’s and Gangadharam’s holdings are highly fact-specific. In Carroll, the court held that the prior art on the in vitro use of an antibiotic did not render its in vivo use obvious because there was a teaching away from in vivo extrapolation for that specific antibiotic. In re Carroll, 601 F.2d at 1186. Carroll does not discuss in vivo extrapolation generally. In Gangadharam, the court simply found that “in this case,” the USP-TO failed to “carr[y] its burden of proving a prima facie case of obviousness” because the sole prior art only made “general reference ... [to] positive results that were obtained ... in an entirely different context, ... and [made only] precatory, encouraging statements relating to uncertain future investigations” of in vivo applications. 1989 WL 127023, at *1-2. Here, in contrast, there is in fact teaching towards the invention.
The dissent also reads Vujanovic, Yan, and Gesano—as well as Miller’s testimony concerning these studies—as creating gen[874]*874uine issues of material fact. The cited passages do not show what Miller argues.’
First, the dissent cites Vujanovic for the teaching that “[w]e suggest that standard in vitro cytotoxicity assays with target cells in suspensions have little relevance in predicting the in vivo antitumor activity of effector cells.” J.A. 962 (emphasis added). This is merely stating that a certain type of experiment setup (“cells in suspension” assay) is not suitable for predicting in vivo results. Indeed, the very next sentence addresses spheroids assays and concludes that “[o]ur results further imply that in vitro assessment of effector cell functions with multicellular CA spheroids [assays] instead of CA cell suspensions [assays] or monolayers [assays] might be of greater relevance in predicting the in vivo therapeutic antitumor potential of immune effector cells.” Id-, see also J.A. 956. Therefore, this passage does not support Miller’s testimony that Vujanovic “caution[s] against relying on in vitro cytotoxicity results.” J.A. 458 (emphasis added).
Second, the dissent cites Yan for the teaching that “our studies suggest that cytotoxic activity towards leukemic cell lines cannot be extrapolated to cells derived directly from patients. The use of such biologic reagents in vitro or in vivo for immunotherapy or purging must be accompanied by careful study of the[ir] ■unique patterns of activity....” J.A. 226. From this, Miller concludes that ‘Yan admonishes against relying on in vitro tests to predict in vivo activity.” J.A. 439-40. However, as discussed above, the cited passage from Yan is speaking about the differences in lysis efficacy against tumors from cell lines versus against tumors derived directly from patients. All of the experiments presented in Yan were performed in vitro (albeit for the purpose of studying the potential of using NK-92 and TALL-104 in vivo). This Yan passage therefore cannot provide support for Miller’s warning against in vivo extrapolation.
Third, the dissent cites Cesano for the teaching that “the sensitivity of the dogs’ tumors to TALL-104 cell lysis in vitro did not appear to be a good indicator of clinical responses.” J.A. 958. This sentence does not address NK-92 and, as discussed above, NK-92 was shown to be more efficacious than TALL-104. Therefore, this would actually teach a skilled artisan toward substituting NK-92 for TALL-104 (as Yan suggested to do).
“When opposing parties tell two different stories, one of which is blatantly contradicted by the record, ... a court should not adopt that version of the facts for purposes of ruling on a motion for summary judgment.” Scott v. Harris, 550 U.S. 372, 380, 127 S.Ct. 1769, 167 L.Ed.2d 686 (2007). That is the situation here. Miller’s reading of the prior art is contradicted by the art itself. Miller’s testimony thus does not raise genuine issues of material fact.
AFFIRMED